These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 33588111)

  • 1. RET Fluorescence In Situ Hybridization Analysis Is a Sensitive but Highly Unspecific Screening Method for RET Fusions in Lung Cancer.
    Radonic T; Geurts-Giele WRR; Samsom KG; Roemen GMJM; von der Thüsen JH; Thunnissen E; Meijssen IC; Sleddens HFBM; Dinjens WNM; Boelens MC; Weijers K; Speel EJM; Finn SP; O'Brien C; van Wezel T; Cohen D; Monkhorst K; Roepman P; Dubbink HJ
    J Thorac Oncol; 2021 May; 16(5):798-806. PubMed ID: 33588111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of clinically actionable gene fusions by next-generation sequencing-based RNA sequencing of non-small cell lung cancer cytology specimens: A single-center experience with comparison to fluorescence in situ hybridization.
    Diks J; Tang Z; Altan M; Anderson S; Chen H; Rashid A; Yang RK; Routbort MJ; Patel KP; Toruner GA; Medeiros LJ; Tang G; Luthra R; Roy-Chowdhuri S
    Cancer Cytopathol; 2024 Jan; 132(1):41-49. PubMed ID: 37747438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of ALK, ROS1, RET fusions and MET exon 14 skipping in NSCLC.
    Melchior L; Hirschmann A; Hofman P; Bontoux C; Concha A; Mrabet-Dahbi S; Vannuffel P; Watkin E; Putzová M; Scarpino S; Cayre A; Martin P; Stoehr R; Hartmann A
    Virchows Arch; 2024 Apr; 484(4):677-686. PubMed ID: 38492039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC.
    Li W; Guo L; Liu Y; Dong L; Yang L; Chen L; Liu K; Shao Y; Ying J
    J Thorac Oncol; 2021 Mar; 16(3):404-418. PubMed ID: 33248323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of
    Reguart N; Teixidó C; Giménez-Capitán A; Paré L; Galván P; Viteri S; Rodríguez S; Peg V; Aldeguer E; Viñolas N; Remon J; Karachaliou N; Conde E; Lopez-Rios F; Nadal E; Merkelbach-Bruse S; Büttner R; Rosell R; Molina-Vila MA; Prat A
    Clin Chem; 2017 Mar; 63(3):751-760. PubMed ID: 28073897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
    Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
    J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare.
    Zhao W; Choi YL; Song JY; Zhu Y; Xu Q; Zhang F; Jiang L; Cheng J; Zheng G; Mao M
    Lung Cancer; 2016 Apr; 94():22-7. PubMed ID: 26973202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene rearrangement detection by next-generation sequencing in patients with non-small cell lung carcinoma.
    Brisudova A; Skarda J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Jun; 164(2):127-132. PubMed ID: 32284620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer.
    Rogers TM; Arnau GM; Ryland GL; Huang S; Lira ME; Emmanuel Y; Perez OD; Irwin D; Fellowes AP; Wong SQ; Fox SB
    Sci Rep; 2017 Feb; 7():42259. PubMed ID: 28181564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion.
    Furugaki K; Mochizuki M; Kohno M; Shu S; Harada N; Yoshimura Y
    BMC Cancer; 2019 Apr; 19(1):301. PubMed ID: 30943926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel targets in non-small cell lung cancer: ROS1 and RET fusions.
    Gainor JF; Shaw AT
    Oncologist; 2013; 18(7):865-75. PubMed ID: 23814043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intergenic Breakpoints Identified by DNA Sequencing Confound Targetable Kinase Fusion Detection in NSCLC.
    Li W; Liu Y; Li W; Chen L; Ying J
    J Thorac Oncol; 2020 Jul; 15(7):1223-1231. PubMed ID: 32151779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell block-based RNA next generation sequencing for detection of gene fusions in lung adenocarcinoma: An institutional experience.
    Wei S; Talarchek JN; Huang M; Gong Y; Du F; Ehya H; Flieder DB; Patchefsky AS; Wasik MA; Pei J
    Cytopathology; 2023 Jan; 34(1):28-34. PubMed ID: 36062384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients.
    Song Z; Yu X; Zhang Y
    Cancer Biol Ther; 2017 Nov; 18(11):883-887. PubMed ID: 27635639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma.
    Lee SE; Lee B; Hong M; Song JY; Jung K; Lira ME; Mao M; Han J; Kim J; Choi YL
    Mod Pathol; 2015 Apr; 28(4):468-79. PubMed ID: 25234288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fusion proteins in lung cancer: addressing diagnostic problems for deciding therapy.
    Zito Marino F; Alì G; Facchinetti F; Righi L; Fontanini G; Rossi G; Franco R
    Expert Rev Anticancer Ther; 2021 Aug; 21(8):887-900. PubMed ID: 33715580
    [No Abstract]   [Full Text] [Related]  

  • 17. Ligation-dependent RT-PCR: a new specific and low-cost technique to detect ALK, ROS, and RET rearrangements in lung adenocarcinoma.
    Piton N; Ruminy P; Gravet C; Marchand V; Colasse É; Lamy A; Naoures Mear CL; Bibeau F; Marguet F; Guisier F; Salaün M; Thiberville L; Jardin F; Sabourin JC
    Lab Invest; 2018 Mar; 98(3):371-379. PubMed ID: 29251734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From genotype to phenotype: Are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements?
    Plodkowski AJ; Drilon A; Halpenny DF; O'Driscoll D; Blair D; Litvak AM; Zheng J; Moskowitz CS; Ginsberg MS
    Lung Cancer; 2015 Nov; 90(2):321-5. PubMed ID: 26424208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non-small-cell Lung Cancer: Implications of FISH-positive Patterns.
    Clavé S; Rodon N; Pijuan L; Díaz O; Lorenzo M; Rocha P; Taus Á; Blanco R; Bosch-Barrera J; Reguart N; de la Torre N; Oliveras G; Espinet B; Bellosillo B; Puig X; Arriola E; Salido M
    Clin Lung Cancer; 2019 Jul; 20(4):e421-e429. PubMed ID: 30898567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
    Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
    Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.